key: cord-0811849-si3pxrgy
authors: Shah, Mili; Captain, Jignasha; Vaidya, Vidyadhar; Kulkarni, Arvind; Valsalkar, Kedar; Nair, Pradeep M.K.; Ganu, Gayatri
title: Safety and efficacy of ozone therapy in mild to moderate COVID-19 patients: A Phase 1/11 Randomized control Trial (SEOT study)
date: 2020-12-23
journal: Int Immunopharmacol
DOI: 10.1016/j.intimp.2020.107301
sha: 2ad18df391954addfe4f83374eb15dbc645a835d
doc_id: 811849
cord_uid: si3pxrgy

Introduction The Corona virus disease 19 (COVID-19) has accounted for multiple deaths and economic woes.While the entire medical fraternity and scientists are putting their best feet forward to find a solution to contain this deadly pandemic, there is a growing interest in integrating other known alternative therapies in to standard care. This study is aimed at evaluating the safety and efficacy of ozone therapy (OT), as an adjuvant to the standard of care (SOC). Methods In the current randomized control trial, 60 patients with mild to moderate score NEWS score were included in two parallel groups (n=30/group). The interventional group (OZ) received ozonizedrectal insufflation and minor auto haemotherapy, daily along with SOC, while the control group (ST) received SOC alone. The main outcome measures included changes in clinical features, oxygenation index (SpO2), NEWS score, Reverse transcription polymerase chain reaction(RT-PCR), inflammatory markers, requirement of advanced care, and metabolic profiles. Results The OZ group has shown clinically significant improvement in the mean values of all the parameters tested compared to ST Group. However, statistical significant were only observed in RT-PCR negative reaction (P=0.01), changes in clinical symptoms (P<0.05) and requirement for Intensive care (P<0.05). No adverse events were reported in OZ group, as against 2 deaths reported in ST group. Conclusion OT when integrated with SOC can improve the clinical status and rapidly reduce the viral load compared to SOC alone, which facilitate early recovery and check the need for advanced care and mortality as demonstrated in this study. This trial is registered in Clinical Trial Registry of India with registration number CTRI/2020/07/026354.

The Corona virus disease has accounted for multiple deaths and economic woes.While the entire medical fraternity and scientists are putting their best feet forward to find a solution to contain this deadly pandemic, there is a growing interest in integrating other known alternative therapies in to standard care. This study is aimed at evaluating the safety and efficacy of ozone therapy (OT), as an adjuvant to the standard of care (SOC).

In the current randomized control trial, 60 patients with mild to moderate score NEWS score were included in two parallel groups (n=30/group). The interventional group (OZ) received ozonizedrectal insufflation and minor auto haemotherapy, daily along with SOC, while the control group (ST) received SOC alone. The main outcome measures included changes in clinical features, oxygenation index (SpO 2 ), NEWS score, Reverse transcription polymerase chain reaction(RT-PCR), inflammatory markers, requirement of advanced care, and metabolic profiles.

The OZ group has shown clinically significant improvement in the mean values of all the parameters tested compared to ST Group. However, statistical significant were only observed in RT-PCR negative reaction (P=0.01), changes in clinical symptoms (P<0.05) and requirement for Intensive care (P<0.05). No adverse events were reported in OZ group, as against 2 deaths reported in ST group.

Corona Virus infection has bedevilled the common public, health care providers, researchers and policy makers to a great extent having been declared as a pandemic by World Health Organization in March 2019. COVID-19 is clinically characterized with fever and cough, breathing difficulties and along with other nonspecific symptoms, like headache, vomiting, diarrhoea etc. [1] Since the first case reported in Wuhan in December 2019, by June 2020, as it stands now,213 countries have reported to have COVID-19 cases in their respective countries, ofwhich United States of America, Brazil, Russia, India and United Kingdom arethe most affected countries. [2] Prevention and quarantine are considered as a major resort against this deadly virus in the absence of any effective vaccine or anti-viral drugs. [3, 4] A wide range of strategies like anti-viral dosages, oxygen supplementation, plasma therapy are being used for managing the symptoms. [3] Due to this uncertainty around management of COVID-19, there has been a lot of interest in exploring the role of adjuvant therapies that can complement mainstream care. [5] [6] [7] [8] Medical Ozone therapy is one such complementary therapy which is reckoned to have strong immune-modulator, anti-oxidant and germicidal effect on humans. [7, [9] [10] [11] The common mode of ozone applications are Ozone autohemotransfusion, direct injection via the intramuscular/intradiscal/paravertebral, rectal,nasal, oral, vaginal insufflations, Cutaneous exposureof the body in a chamber or bag and saline. [12] Brief reports exploring the use of ozone therapy as an adjuvant/potential therapeutic tool in treating COVID-19 suggests a possible antagonizing action of ozone against Corona virus. [7, [13] [14] [15] [16] [17] One of these studies has hinted on a possibility of early recovery and reduction in length of hospital stay on patients who underwent ozone therapy compared to others. [16] Barring a few clinical/observational studies, most of the studies in Ozone and COVID-19 are reviews that warrant more clinical studies to strengthen the recommendation of Ozone as a therapy in COVID-19. This study evaluates the safety and effectiveness of the ozone therapy as an adjuvant treatment for patients displaying mild to moderate stage of COVID-19.

The study was a randomized control trial comprised of patients who were enrolled for COVID care in a Dedicated COVID care setting in India. The study was approved by the Institutional Ethics Committee and was registered with Clinical Trial Registry of India with registration number CTRI/2020/07/026354. The CONSORT flow of the entire study is depicted in Figure   1 

Adults of age 30 to 60 of both sex with positive Reverse transcription polymerase chain reaction (RT-PCR) from nasopharyngeal swab test result presenting mild to moderately severe disease (NEWS score ≤ 8) [18] and willing to provide informed consent were included in the study.

Participants requiring Intensive Care Unit (ICU) admission and or artificial ventilation or any other co-morbidity (which were at critical stage at screening), were excluded from the study.

Participants with chronic constipation for more than 7 days at the time of screening or with glucose-6-phosphate-dehydrogenase deficiency (G6PD) deficiency, were excluded fromthe study. Participants from the vulnerable group like pregnant and breastfeeding women were excluded from the study.

We screened 63 participants of which 60 participants were enrolled into the study. They were randomized using a computer generated randomization sheet, either in the standard treatment arm (ST Group)where the patients were provided with conventional care as recommended in Clinical management protocol for COVID 19 advocated by Indian Council of Medical Research (ICMR), Ministry of Health and Family Welfare, Government of India [19] or to the treatment arm where the patients were treated with ozone therapy along with the standard protocol (OZ group). See Figure 1 for the flow of event this trial.

The trial was designed as a superiority trial assuming the number of RT-PCR negative patients in the ST group as 66% and in OZ group as 90%. To achieve this difference (d) of 24% and level of significance (α) 0.05 for a superiority margin (δ) of 5% and for a power (β) of 80%, the sample size required was calculated as 30 (n=30) per arm and total number of samples required for the whole study was 60.

As mentioned the control group received Standard of care (SOC) which was provided for 10 days or till a negative report is received via RT-PCR test,whichever was earlier, starting from the patient's hospitalization date (after confirming positive RT-PCR for COVID 19) . SOC treatment was continued as per the ICMR protocol.Each patient from the OZ groupreceived SOC and Ozone therapy. The ozone therapy included 40 micrograms/ml ozone in the dose of about 150 ml twice daily as a rectal insufflation [20] and 2-3 ml venous blood along with 5 ml Ozone at 25 micrograms/ml [minor auto haemotherapy (MiAHT)] [21] once daily along with SOC. The ozone/oxygen mixture was generated from an ozone generator for medical use (O3-Ozonics generator, Ozone Forum of India), which is automated and standardized for time, volume and concentration.

The total duration of treatment per patient was kept as 10 days, which is excluding 2 days screening period. A screening window of 2 days was kept, in case of delay in availability of tests reports or in case few tests needed to be repeated. Day 0 was considered as baseline visit and day 1 to 9 was considered as intervention period. End of study visit was at day 10 or negative report form RT-PCR tests whichever wasearlier.

This study looked at a variety of outcome variables related to the prognosis of COVID 19. The  Hospitalized, on non-invasive ventilation or high flow oxygen devices (3)  Hospitalized, requiring supplemental oxygen (4)  Hospitalized, not requiring supplemental oxygen (5)  Not hospitalized (6)

The efficacy analysis was performed in the per-protocol (PP) population defined as those patients who had good treatment compliance, who did nottake any prohibited medications (Other than Ozone therapy and SOC treatment, any other health supplements, nutraceuticals, Ayurvedic, Homeopathic, Siddha, Unani drug(s) or any other traditional or folklore medicine or therapy during the study period)and whose CRF was complete as requested. Both descriptive and inferential analyses were used in inferring the data. at each follow up from baseline within and between groups by using Student T test.

Parameters:Secondary variables that are mean change in the NEWS score compared to the baseline on day 5 and 10 day were analyzed and compared by using Wilcoxon sign rank test for with in changes and Mann Whitney U test to compare the change between two groups.Other Laboratory data and vital parameters were analyzed and compared by using student t test.

Adverse events (AEs) and serious adverse events (SEs) will be summarised, counting both the number of separate events and the number of subjects experiencing events occurring during the study period will be provided overall, per system organ class and preferred term by presenting. All p-values were reported based on two-sided significance test and all the statistical tests were interpreted at 5% level of the significance level.

There were total of 63 subjects screened of which 3 were screen failure having uncontrolled diabetes and not on stable medication.The mean age of participants in the ST group (22 males; 8 females) was 43.60±9.72 years and 44± 8.66years in OZ group (26 males; 4 females). Out of 30 randomized subjects from ST group, two subjects met with fatality as a result of progression of disease. Around 10% of the cases from ST group had Diabetes mellitus, which was comparable with 10% among OZ group having diabetes and hypertension and thus difference was not significant.

On day 5, 77% of cases from OZ group and 53% in ST group showed RT-PCR negative result.

At the end of Day 10, 100% of the cases showed PCR negativity in OZ group which is significantly more as compared to 70% in standardtreatment group. The changes were statistically significant (P = 0.01) in OZ group compared to ST group.

In OZ group by the end of Day 5, 30% of patients were relieved of cough which were significant from baseline and the same trend continued till day10. 100% subjects from OZ group were relieved of cough on day 10, whereas 75% cases from ST were showing mild cough. The shift from mild cough to no cough was statistically significant (P < 0.05) in OZ group compared to ST group.

In OZ group, 90% of cases were relieved of breathlessness on day 5, which were significant from baseline and the same trend was continued till day 10. On day 10, test group demonstrated 100% subjects with relieved breathlessness which was 91% in standard group. There was significant difference (P < 0.05) in breathlessness score between the OZ and ST groups.

In the present study, within ozone treated group, there was reduction in all three inflammatory biomarkers from baseline to end of study. There was 21.29 %, 30% and 25 % decrease in mean levels of CRP, LDH and ferritin respectively at end of the study compared to baseline.The same was observed in ST group as well, however, the magnitude of change was predominant in OZ group.The results are tabulated in table 1.The changes were statistically not significant.

In this study 0% of cases from OZ group required ICU admission whereas there were 10% participants who required ICU admission in ST group due to poor prognosis. There was no supplemental oxygen requirement in Ozone group and not a single fatality in ozone treated group. However, 2 fatalities were reported in the ST group due to progression of COVID-19.

Comparison between the two groups on Fisher Exact Test indicated a statistically significant (P<0.05) change. (Table 5) 

In both ST and OZ group the mean SpO2 improved in magnitude from baseline to end of study.

However, the changes were not statistically significant (P>0.05). Results are tabulated in table 1.

There was significant change in the mean values of NEWS score in both groups compared to the baseline. The change was more predominant in the OZ group; however, the changes were not statistically significant. Results are tabulated in table 1.

Neither the OZ group nor the ST group showed any significant changes in lipid profile, liver profile, renal profile and serum electrolytes such as sodium, potassium and chloride. Results are tabulated in table 2, 3 and 4 respectively.

Our trial has found that Ozone therapy when administered with SOC has significantly improved the time to clinical improvement, mortality, or time to clearance of virus in patients with mild to moderate COVID-19, compared to patients who received only SOC. To our knowledge this is the first trial directly reporting the safety and efficacy of Ozone in mild to moderate COVID There were few reports suggesting the use of Ozone therapy in COVID-19 treatment prophylaxis. [7, [13] [14] [15] 17, 22, 23] These reports/studies suggested a potential role of ozone in COVID-19, further it recommended well-designed clinical trials to assess probable ozone concentration, possible routes of administration, safety, stage of the disease in which ozone to be administered, contraindications, concomitant administration of antioxidants etc.

In the present study, Ozone was compared for its safety and clinical efficacy along with standard treatment in COVID 19 patients. The results are promising as it has shown improvement in multiple variables tested compared to the ST group. In COVID-19 though there is multi-organ involvement, respiratory system is the most affected in which dyspnoea is the most predominant symptom. [24, 25] Though statistically not-significant OZ group demonstrated increase in SpO2 levels during the study period compared to baseline,which might be the reason for reduced breathlessness that has reduced the patients risk profile and signifies good prognosis about the disease.

Participants from OZ group didn't show any requirement of supplemental oxygen, ICU admission andmechanical ventilation whereas standard group demonstrated 10% subjects requiring mechanical ventilation, ICU admission and two of which led to two fatalities. The results on mortality and need for advanced care in both groups in our study were comparatively better than the preliminary report published on Ozone safety among COVID-19 patients. [26] This indicates the need to integrate Ozone therapy in to the existing care. Integrating Ozone therapy in COVID-19 care not only reduces the mortality but also will be very strategic to accelerate recovery of COVID 19 patients presenting mild to moderate severity to getting into the advanced COVID-19 stages.

There is strong relationship between symptom regressions and severity of COVID 19. [27] Our results that subjects in OZ group were relieved of cough, breathlessness more effectively than ST group that can check the severity of COVID-19.

One of the strong correlation to avoid bad prognosis in COVID 19, is to exert faster reduction in viral titre. [28] Antiviral activity can reduce pulmonary infiltrates and pulmonary tissue damage. There were 77% subjects from Ozone treated group showed negative RT-PCR on day 5 and all 100% got negative RT-PCR on day 10. This clearly declares advantage of faster eradication of virus from body which could be attributed to the antiviral potential of Ozone therapy.

In the present study that compared ST group to OZ group,we see a greater magnitude of reduction in mean NEWS score in OZ group,indicating lesser risk profiling,giving patients a fair chance to aster clinical recovery.In addition to the reduction in NEWS score, OZ group has shown significant reduction in all symptoms associated with COVID-19.

Ozone treated group eventually required reduced hospital stay (Mean duration: ST Group 9 days; OZ group 8 days) as compared to standard, though the change was insignificant. It is a profound fact that there was no ICU admission, supplemental oxygen and mechanical ventilation requirement in ozone treated group. Thus the Ozone treated group has brought the healthcare requirement of above said parameters to zero. Patients subjected to Ozone Therapy showed 100% tolerance at the end of the study. This efficacy of ozone in COVID 19 may be attributed to its cytokine modulation, [29] direct or indirect oxidation of viruses and by stimulating cellular and humoral responses. [17] The results of our study encourages the use of Ozone as an adjuvant in mild to moderate patients of COVID 19 .The present research confirms safety and efficacy of the ozone therapy in COVID 19 patients. However, large scale multi-centric study with larger sample size is warranted.

Our study suggests that Ozone therapy is safe and effective to be used in COVID-19 patients who are in mild or moderate stage of the illness. Governments and policy makers should consider including Ozone therapy in the existing level of care which could possibly reduce the requirement of advanced treatment facilities and reduce morbidity and mortality rate. However, future studies are warranted to understand the magnitude of this change in these multiple domains that are affected by COVID-19. 

Clinical characteristics of refractory COVID-19 pneumonia in

Immune-mediated approaches against COVID-19

The Pathogenesis of Coronavirus Disease 2019 (COVID-19): Evaluation and Prevention

Treatment for severe acute respiratory distress syndrome from COVID-19

Public Health Approach of Ayurveda and Yoga for COVID-19 Prophylaxis

Time to realise the true potential of Ayurveda against COVID-19

Two known therapies could be useful as adjuvant therapy in critical patients infected by COVID-19

Efficacy and safety of Chinese herbal medicine for Coronavirus disease 2019: A protocol for systematic review and meta-analysis, Medicine (Baltimore)

Ozone therapy as a primary and sole treatment for acute bacterial infection: case report

Ozone efficacy for the control of airborne viruses: Bacteriophage and norovirus models

Ozone and oxidation therapies as a solution to the emerging crisis in infectious disease management: a review of current knowledge and experience

Scientific and medical aspects of ozone therapy. State of the art

Oxygen-ozone (O(2)-O(3)) immunoceutical therapy for patients with COVID-19. Preliminary evidence reported

Potential Cytoprotective Activity of Ozone Therapy in SARS-CoV-2/COVID-19

Ozone Therapy as a Possible Option in COVID-19 Management , Front. Public Heal

A preliminary evaluation on the efficacy of ozone therapy in the treatment of COVID-19

Ozone (O3) and SARS-CoV-2: Physiological Bases and Their Therapeutic Possibilities According to COVID-19 Evolutionary Stage, SN Compr

NEWSDIG: The National Early Warning Score Development and Implementation Group

Effect of Rectal Ozone (O(3)) in Severe COVID-19 Pneumonia: Preliminary Results, SN Compr

The effect and safety of ozone autohemotherapy combined with pharmacological therapy in postherpetic neuralgia

Ozone therapy in COVID-19: A narrative review

Potential mechanisms by which the oxygen-ozone (O2-O3) therapy could contribute to the treatment against the coronavirus COVID-19

Hypoxia in COVID-19: Sign of Severity or Cause for Poor Outcomes

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Ozone as adjuvant support in the treatment of COVID-19: A preliminary report of probiozovid trial

Identification of Symptoms Prognostic of COVID-19 Severity: Multivariate Data Analysis of a Case Series in Henan Province

Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2

Modulation of ozone-induced airway hyperresponsiveness and inflammation by interleukin-13

The authors would like to thanks all the patients and support staff that has supported us in completing this study.Funding: This study was supported by Bisleri Charitable Trust, India

1=Death, 2=Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation, 3=Hospitalized, on non-invasive ventilation or high flow oxygen devices 4=Hospitalized, requiring supplemental oxygen, 5= Hospitalized, not requiring supplemental oxygen, 6=Not hospitalized At baseline all the subjects from both groups were hospitalized and not requiring supplemental oxygen. From the second day one subject from standard group went on to non-invasive ventilation or high flow oxygen devices and got shifted to ICU. On day 5 two subjects from standard group were on non-invasive ventilation or high flow oxygen devices and admitted to ICU. On day 6th there was one fatality in standard group related to progression of disease. On Day 7 there was second subject from standard group in ICU showed bad prognosis resulted in second fatality.